SUNNYVALE, Calif. -- (Business Wire)

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, has posted to its Web site a White Paper discussing the investment opportunity in the Company’s LymPro Test® for Alzheimer’s disease from a scientific perspective. The White Paper can be found at http://ir.stockpr.com/amarantus/scientific-publications.

“The LymPro Test is potentially the first blood-based diagnostic for Alzheimer’s, and could represent a significant advancement in the ability to detect the disease at an early stage,“ said Amarantus Chief Executive Officer Gerald Commissiong. “This new White Paper is a valuable tool for anyone who wants a better understanding of Alzheimer’s, the recent scientific literature on the disease and most importantly the investment thesis behind our in-license of LymPro.”

Prepared by Adam J. Simon, Ph.D., a member of the Amarantus Board of Advisors, the White Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, the scientific underpinnings of the LymPro Test, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.

About Amarantus

Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in treating Parkinson’s disease, as well as statements about expectations, plans and prospects of the development of Amarantus' diagnostic product candidates for Parkinson’s and Alzheimer’s disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Contacts:

Investor/Media Contacts:
Amarantus
Russell Miller
Director of Investor Relations
408-737-2734 x 109
ir@amarantus.com
or
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com

Source: Amarantus BioScience Holdings, Inc.